Consumer Health Results Roundup: Genomma, Ipsen And Taisho
Mexico's Genomma enjoys good growth in the second quarter, while Japan's Taisho records a steady start to its new financial year. Meanwhile, France's Ipsen endures a difficult period as its biggest OTC brand falters.
You may also be interested in...
Taisho Wraps BMS Consumer Health Acquisition; iAnthus Nabs CBD For Life; Health & Wellness M&A In Brief
Bristol-Myers Squibb is free to focus on drug development for patients facing serious diseases, with the divestment of its UPSA consumer health business to Taisho now complete. Separately, Harvest One Cannabis and iAnthus Capital Holdings build their capabilities to meet soaring demand for CBD and other cannabis-derived health, wellness and beauty products.
The latest European consumer health people news: Sanofi Consumer Healthcare's Van Rycke named CEO of UPSA; Bionorica's global business head steps down; MHRA names its first chief safety officer.
Australian-heritage supplements brand Swisse has secured the rights to use ChromaDex' patented Niagen ingredient - marketed to help consumers "age better" - in a new product range.